Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, represents a heterogeneous and aggressive breast cancer (BC) subtype associated with a high recurrence risk [1]. Accounting for approximately 8 %–13 % of all breast cancers, TNBC demonstrates the poorest prognosis among molecular subtypes and has limited effective treatment options [2]. Neoadjuvant chemotherapy (NAC) i…